Skip to content

Genetics Of Autoimmunity In Type I Diabetes

Genetics Of Autoimmunity In Type I Diabetes

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03648918
Enrollment
4000
Registered
2018-08-28
Start date
2001-08-01
Completion date
2050-01-01
Last updated
2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Diabetes Mellitus, Type 1, Type1diabetes, Type1 Diabetes Mellitus

Keywords

Family, Healthy Controls, Siblings

Brief summary

The purpose of this study is to gain more information about the step-by-step process that causes someone to develop type 1 diabetes. Scientists think that a person's own immune system, directed by genetic and environmental factors play a major role in its development. Participation involves a blood draw, a brief medical history questionnaire and measurements of height and weight. Some participants will be asked to return for annual follow-up visits for 10 years.

Detailed description

The goal of this project is to gain knowledge about the development of Type 1 diabetes (T1D), as T1D is one of the most common chronic diseases in children. There has been a rise in the number of cases diagnosed as well as a decrease in the age of diagnosis. This project aims to understand the disease progression as seen in the immune system and to define the genetic and environmental factors that affect inflammation and regulation, which could determine disease progression or nonprogression. Families that include a family member with T1D will be recruited, as well as unrelated, healthy controls as a comparison group. Participants will have height and weight measured, complete a social & medical history questionnaire, and have blood drawn for analysis for HLA haplotype (a genetic sequence related to type 1 diabetes susceptibility)diabetes, blood glucose, immune system response, complete blood count, and autoantibody measurements. Some family members may return for follow-up visits for up to 10 years.

Interventions

OTHERBlood Collection

Blood will be collected via venipuncture and analyzed. Blood samples will be analyzed for HLA haplotype (a genetic sequence related to type 1 diabetes susceptibility), plasma-induced signature, diabetes autoantibodies, complete blood count with differential, and serum and plasma for storage. For family members with diabetes, blood will also be tested for A1c.

Sponsors

Medical College of Wisconsin
Lead SponsorOTHER
Benaroya Research Institute
CollaboratorOTHER
Indiana University
CollaboratorOTHER

Study design

Observational model
FAMILY_BASED
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
2 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

(Families): * Families where at least one first-degree family member has type 1 diabetes * The diabetic proband in the family was diagnosed before the age of 39 * Family members must be at least 2 years old to participate

Exclusion criteria

(Families): * Families with no history of type 1 diabetes * Families with a history of diabetes that is not type 1 (LADA, MODY, type 2 etc.) Inclusion Criteria (Controls): * No family history of type 1 diabetes or other autoimmune conditions * Age 2 or older

Design outcomes

Primary

MeasureTime frameDescription
Onset of Type 1 diabetesUp to 10 yearsThe primary outcome is the development of diabetes as defined by the American Diabetes Association (ADA) based on the presence of symptoms and unequivocal hyperglycemia.
Autoantibody MeasurementUp to 10 yearsPresence or absence of the autoantibodies related to type 1 diabetes: IA-2 (islet antigen), GAD65 (pancreatic islet cell autoantibody), IAA (insulin autoantibody), ZnT8 (zinc transporter 8)

Countries

United States

Contacts

CONTACTMartin Hessner, PhD
t1dinfo@mcw.edu414-955-4903
PRINCIPAL_INVESTIGATORMartin Hessner, PhD

Medical College of Wisconsin

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 17, 2026